Fennec Pharmaceuticals (FENC) Company Overview

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company's approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management (“Petrichor”).

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call.

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations Into at Least 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call.

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m.